XML 8 R2.htm IDEA: XBRL DOCUMENT v3.25.3
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2025
Dec. 31, 2024
CURRENT ASSETS    
Included within cash and cash equivalents $ 40,463 $ 45,789
Marketable securities 23 2,016
Accounts receivable 127 638
Prepaid expenses and other current assets 1,647 2,554
Total current assets 42,260 50,997
NONCURRENT ASSETS    
Property and equipment, net 2,157 2,251
Operating lease right-of-use assets 2,311 2,144
Deposits and other long-term assets 539 614
Goodwill [1] 10,672 10,672
Intangible assets, net 31,700 46,540
TOTAL ASSETS 89,639 113,218
CURRENT LIABILITIES    
Accounts payable and accrued liabilities 4,550 5,437
Operating lease liabilities, current portion 1,023 1,097
Finance lease liabilities, current portion 43 55
Deferred revenues, current portion 3,766 7,388
Total current liabilities 9,382 13,977
LONG-TERM LIABILITIES    
Deferred tax liability 273 273
Deferred revenues, net of current portion 12,462 14,433
Operating lease liabilities, net of current portion 1,515 1,295
Finance lease liabilities, net of current portion 40 67
Warrant liabilities 45,171 6,161
TOTAL LIABILITIES 68,843 36,206
Commitments and contingencies (Note 13)
SHAREHOLDERS' EQUITY    
Preferred shares, no par value, 2,000 shares authorized; none issued and outstanding as of September 30, 2025 and December 31, 2024
Common shares, no par value, 450,000 shares authorized as of September 30, 2025 and December 31, 2024; 230,328 and 220,416 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively 494,175 484,722
Accumulated other comprehensive loss (4,286) (2,876)
Accumulated deficit (467,849) (403,465)
Lineage's shareholders' equity 22,040 78,381
Noncontrolling deficit (1,244) (1,369)
Total shareholders’ equity 20,796 77,012
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY $ 89,639 $ 113,218
[1] Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired and liabilities assumed in connection with our acquisition of Asterias Biotherapeutics, Inc. (“Asterias”) in March 2019 (the “Asterias Merger”). The Company conducted a qualitative goodwill assessment for the second quarter of 2025 and took into consideration the impairment of the VAC indefinite-lived intangible asset. After assessing the totality of relevant events and circumstances, there was no impairment to the goodwill carrying value as of June 30, 2025, and to date, the Company has not recognized any goodwill impairment.